Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma

SIMPLE SUMMARY: We sought to identify molecular mechanisms of lower efficacy of immunotherapy in epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma and the differences in those mechanisms with the emergence of tyrosine kinase inhibitor (TKI)-resistance. To this end, we conducted affi...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yue A., Maity, Tapan K., Gao, Shaojian, Gong, Tao, Bahta, Meriam, Venugopalan, Abhilash, Zhang, Xu, Guha, Udayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507780/
https://www.ncbi.nlm.nih.gov/pubmed/34638461
http://dx.doi.org/10.3390/cancers13194977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507780/
https://www.ncbi.nlm.nih.gov/pubmed/34638461
http://dx.doi.org/10.3390/cancers13194977

Ejemplares similares